Ocular Surface Disease Clinical Trial
Official title:
Novel Use of Restasis (Cyclosporine Ophthalmic Emulsion 0.05%) on Application of PROSE Devices for Management of Patients With Ocular Surface Disease: A Pilot Study
The goal of this prospective observational pilot study is to evaluate the tolerability and safety of RESTASIS (cyclosporine ophthalmic solution 0.05%) when added to the PROSE (Prosthetic Replacement of the Ocular Surface Ecosystem) lens reservoir in patients with ocular surface disease (OSD). Secondary endpoints include early (1-month) efficacy data for ocular signs and symptoms.
For this study, all subjects will receive Restasis (Cyclosporine ophthalmic emulsion 0.05%). One drop of the dispensed study drop will be instilled in the PROSE lens reservoir twice a day and the remainder of the reservoir will be filled with normal saline (0.9% sodium chloride solution). In order to standardize solutions used in the PROSE reservoir, all patients recruited will be either currently using or will be switched to buffered preservative-free normal saline (Purilens, Lifestyle Inc., pH 7.46 ) to better match the reported pH of RESTASIS (pH 6.5-8.05 ). Outcomes will include subjective responses regarding the subject's symptoms and visual function in addition to the objective assessments of the health of the ocular surface seen on clinical examination. Results will be measured at baseline, after 1 week, and after 1 month of the study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04067973 -
Impact of Prematurity on the Optic Nerve
|
||
| Completed |
NCT04828057 -
Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
|
||
| Not yet recruiting |
NCT06375343 -
Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®
|
Phase 1 | |
| Completed |
NCT00346450 -
Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation
|
Phase 3 | |
| Completed |
NCT04351100 -
Efficacy of Diacerein on Ocular Surface Disease in Degenerative Arthritis Patients
|
||
| Completed |
NCT03659955 -
Autologous Blood Treatment for Ocular Surface Disease
|
N/A | |
| Completed |
NCT04536129 -
Effects of Topical Low Dose Preservative-free Hydrocortisone on Intraocular Pressure
|
N/A | |
| Completed |
NCT01254370 -
Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease
|
Phase 2 | |
| Completed |
NCT00554411 -
Assessing Ocular Surface Changes After Changing Glaucoma Medications
|
N/A | |
| Completed |
NCT03769454 -
A Phase I Study of PP-001 Eye Drops in Healthy Adult Volunteers
|
Phase 1 | |
| Recruiting |
NCT06256770 -
Evaluation of the Safety and Efficacy of Rigid Breathable Scleral Contact Lenses for the Correction of Ametropia
|
||
| Completed |
NCT04673604 -
From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy
|
N/A | |
| Not yet recruiting |
NCT06370585 -
Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF
|
Phase 1 | |
| Withdrawn |
NCT04735510 -
Novel Use of Restasis and PROSE Devices
|
Phase 3 | |
| Suspended |
NCT00348114 -
Transplantation of Cultivated Limbal Epithelium on Amniotic Membrane for Limbal Stem Cell Deficiency
|
Phase 2 | |
| Recruiting |
NCT04010422 -
Ocular Function in Autism Spectrum Disorder
|
||
| Completed |
NCT05528016 -
Short and Long-term Results of Skin Versus Skin Plus Orbicularis Resection Blepharoplasty
|
N/A | |
| Completed |
NCT04452279 -
Ocular Surface Disease Changes After iStent or iStent Inject Implantation With Phacoemulsification
|
N/A | |
| Completed |
NCT04535388 -
LK Scleral Lens for Patients With Intractable Ocular Surface Diseases
|
N/A | |
| Recruiting |
NCT06298890 -
The Pattern of Dry Eye Disease After Cataract Surgery
|